Innovative treatments, with a main focus on advanced treatments in PD, disease modification and the role of pharmacogenetics. Our TULIP cohort consists of 160 GBA1 patients, part of a national GBA1 cohort of over 500 patients, in which the clinical course of the different mutations is established. The TULIP cohort is also the basis for new therapeutics, focussing on lysosomal hypo/dysfunction, in order to modify the course of PD.
At this moment, the use of medication in PD is based on trial and error, which has to become more personalised, using a medication passport for PD patients. This passport is now being created and tested, including all genetic variants of receptors and enzymes, involved in the dopaminergic and cholinergic treatment of PD patients.